Compare LND & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LND | OCGN |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.6M | 387.3M |
| IPO Year | 2006 | N/A |
| Metric | LND | OCGN |
|---|---|---|
| Price | $3.57 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 47.0K | ★ 3.7M |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,991,256.00 | $5,370,000.00 |
| Revenue This Year | $40.80 | $35.93 |
| Revenue Next Year | $5.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.26 |
| 52 Week Low | $3.47 | $0.52 |
| 52 Week High | $4.03 | $1.90 |
| Indicator | LND | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 54.79 |
| Support Level | $3.61 | $1.37 |
| Resistance Level | $3.61 | $1.52 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.22 | 57.50 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").